Factors associated with upstaging in patients preoperatively diagnosed with ductal carcinoma in situ by core needle biopsy

References

1. 1.↵
   2. Ozkan-Gurdal S,
   3. Cabioglu N,
   4. Ozcinar B,
   5. Muslumanoglu M,
   6. Ozmen V,
   7. Kecer M, et al.

   Factors predicting microinvasion in ductal Carcinoma in situ. Asian Pac J Cancer Prev. 2014;15:55–60.

   OpenUrl
2. 2.↵
   2. Van Zee KJ.

   Use of axillary staging in the management of ductal carcinoma in situ. JAMA Oncol. 2015;1:332–3.

   OpenUrl
3. 3.↵
   2. Zetterlund L,
   3. Stemme S,
   4. Arnrup H, et al.

   Incidence of and risk factors for sentinel lymph node metastasis in patients with a postoperative diagnosis of ductal carcinoma in situ. Br J Surg. 2014;101:488–94.

   OpenUrlCrossRefPubMed
4. 4.↵
   2. Sakr R,
   3. Barranger E,
   4. Antoine M,
   5. Prugnolle H,
   6. Daraï E,
   7. Uzan S.

   Ductal carcinoma in situ: value of sentinel lymph node biopsy. J Surg Oncol. 2006;94:426–30.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   2. Ernster VL,
   3. Barclay J,
   4. Kerlikowske K,
   5. Wilkie H,
   6. Ballard-Barbash R.

   Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med. 2000;160:953–8.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   2. Brennan ME,
   3. Turner RM,
   4. Ciatto S,
   5. Marinovich ML,
   6. French JR,
   7. Macaskill P, et al.

   Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology. 2011;260:119–28.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   2. Lyman GH,
   3. Temin S,
   4. Edge SB,
   5. Newman LA,
   6. Turner RR,
   7. Weaver DL, et al.

   Sentinel lymph node biopsy for patients with early-stage breast cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2016;32:1365–83.

   OpenUrl
8. 8.↵
   2. Kim J,
   3. Han W,
   4. Lee JW,
   5. You JM,
   6. Shin HC,
   7. Ahn SK, et al.

   Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision. Breast. 2012;21:641–5.

   OpenUrlCrossRefPubMed
9. 9.↵
   2. Kondo T,
   3. Hayashi N,
   4. Ohde S,
   5. Suzuki K,
   6. Yoshida A,
   7. Yagata H, et al.

   A model to predict upstaging to invasive carcinoma in patients preoperatively diagnosed with ductal carcinoma in situ of the breast. J Surg Oncol. 2015;112:476–80.

   OpenUrl
10. 10.↵
    2. Sun X,
    3. Li H,
    4. Liu YB,
    5. Zhou ZB,
    6. Chen P,
    7. Zhao T, et al.

    Sentinel lymph node biopsy in patients with breast ductal carcinoma in situ: Chinese experiences. Oncol Lett. 2015;10:1932–8.

    OpenUrl
11. 11.↵
    2. Houssami N,
    3. Ciatto S,
    4. Ellis I,
    5. Ambrogetti D.

    Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates. Cancer. 2007;109:487–95.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.
    2. Ciatto S,
    3. Houssami N,
    4. Ambrogetti D,
    5. Bianchi S,
    6. Bonardi R,
    7. Brancato B, et al.

    Accuracy and underestimation of malignancy of breast core needle biopsy: the Florence experience of over 4000 consecutive biopsies. Breast Cancer Res Treat. 2007;101:291–7.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    2. Lee SK,
    3. Yang JH,
    4. Woo SY,
    5. Lee JE,
    6. Nam SJ.

    Nomogram for predicting invasion in patients with a preoperative diagnosis of ductal carcinoma in situ of the breast. Br J Surg. 2013;100:1756–63.

    OpenUrl
14. 14.
    2. Miyake T,
    3. Shimazu K,
    4. Ohashi H,
    5. Taguchi T,
    6. Ueda S,
    7. Nakayama T, et al.

    Indication for sentinel lymph node biopsy for breast cancer when core biopsy shows ductal carcinoma in situ. Am J Surg. 2011;202:59–65.

    OpenUrlPubMed
15. 15.
    2. Chan MYP,
    3. Lim S.

    Predictors of invasive breast cancer in ductal carcinoma in situ initially diagnosed by core biopsy. Asian J Surg. 2010;33:76–82.

    OpenUrlCrossRefPubMed
16. 16.↵
    2. Sue GR,
    3. Lannin DR,
    4. Killelea B,
    5. Chagpar AB.

    Predictors of microinvasion and its prognostic role in ductal carcinoma in situ. Am J Surg. 2013;206:478–81.

    OpenUrlPubMed
17. 17.↵
    2. Walters LL,
    3. Pang JC,
    4. Zhao LL,
    5. Jorns JM.

    Ductal carcinoma in situ with distorting sclerosis on core biopsy may be predictive of upstaging on excision. Histopathology. 2015;66:577–86.

    OpenUrl
18. 18.↵
    2. Rakovitch E,
    3. Nofech-Mozes S,
    4. Hanna W,
    5. Narod S,
    6. Thiruchelvam D,
    7. Saskin R, et al.

    HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer. 2012;106:1160–5.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    2. Davis JE,
    3. Nemesure B,
    4. Mehmood S,
    5. Nayi V,
    6. Burke S,
    7. Brzostek SR, et al.

    Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in situ. Appl Immunohistochem Mol Morphol. 2016;24:20–5.

    OpenUrl
20. 20.↵
    2. Al-Ameer AY,
    3. Al Nefaie S,
    4. Al Johani B,
    5. Anwar I,
    6. Al Tweigeri T,
    7. Tulbah A, et al.

    Sentinel lymph node biopsy in clinically detected ductal carcinoma in situ. World J Clin Oncol. 2016;7:258–64.

    OpenUrl